Mizuho Securities Believes NovoCure Ltd (NASDAQ: NVCR) Won’t Stop Here

By Ryan Adsit

Mizuho Securities analyst Difei Yang maintained a Buy rating on NovoCure Ltd (NASDAQ: NVCR) on June 11 and set a price target of $32. The company’s shares opened today at $31.45, close to its 52-week high of $32.03.

Yang observed:

“We hosted a conference call with a at UCSF yesterday to discuss NovoCure’s Optune technology. We discussed adoption trends, patient compliance and the potential of Optune in cancer indications beyond glioblastoma (GBM). A few of our key takeaways are below.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 20.9% and a 54.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.

NovoCure Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $30.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $32.03 and a one-year low of $14.55. Currently, NovoCure Ltd has an average volume of 880K.

Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NVCR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.